Prospective Observatonal Study for Effect of Duodenojejunal Bypass and Gastric Bypass on T2DM Patients (T2DM)

November 27, 2012 updated by: Inha University Hospital

Metabolic Surgery for Type 2 Diabetes

Surgical treatment for type 2 diabetes has been taken note especially in less obese or non obese patients. In Asian, the nuber of less obses or non obese patients with T2DM is greater than that of the obese.

We are trying to do a prospective observational study for the evaluation of the effect of duidenojejunal bypass and gastric bypass on the glycemoc control in those patients.

The selection criteria are type 2 diabetess, 20-60 years old, BMI 23-34 or 21-22 with viceral obesity, insulin use less than 10 years and the patients understanding the hypothesis of this study, risks, expecting effects and agreeing this study.

We are checking oral GTT, insulin level, C-peptide level, HbA1C, etc. with some anthropometric measurs preoperatively, postoperatively, at 3 month and 12 month.

We will compare the clinical factors at each time.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

20

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • type 2 diabetes
  • HbA1C > 7.0%
  • BMI 23 - 34 or BMI 21-22 with viceral obesity
  • insulin use less than 10 years
  • uncerstanding the risks, hypothesis, expecting effects

Exclusion Criteria:

  • type 1 diabetes
  • C-peptide < 1.0ng/ml
  • BMI < 21
  • severe cardiovascular diseases or their history
  • malignancy or history
  • alcoholics, pituitary failrue
  • history of severe ketosis, diabetic coma or precoma
  • abnormal liver enzyme, over 3 fold of normal level
  • liver cirrhosis or hepatitis
  • serum creatinine > 2.0mg/dL
  • glucocorticoids user
  • diabetes due to other endocrine diseases
  • pancreatic disease
  • anti-GAD Ab (+)
  • the incongruity for surgery

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: gastric bypass, duodenojejunal bypass
Procedure: laparoscopic roux en Y gastric bypass / open duodenojejunal bypass
routine GBP with 80cm roux and biliopancreatic limb

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Hemoglobin A1C
Time Frame: preoperatively, at 3month, at 12 month
change of the level
preoperatively, at 3month, at 12 month

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
oral glucose tolerance test
Time Frame: preopertively, postoperatively, at 3 month, at 12 month
changes of the level at each time
preopertively, postoperatively, at 3 month, at 12 month

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
insulin level
Time Frame: preoperatively, postoperatively, at 3 month, at 12 month
change the levels
preoperatively, postoperatively, at 3 month, at 12 month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Inha University Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

December 1, 2009

Primary Completion (Actual)

December 1, 2011

Study Completion (Actual)

October 1, 2012

Study Registration Dates

First Submitted

November 24, 2012

First Submitted That Met QC Criteria

November 27, 2012

First Posted (Estimate)

November 28, 2012

Study Record Updates

Last Update Posted (Estimate)

November 28, 2012

Last Update Submitted That Met QC Criteria

November 27, 2012

Last Verified

November 1, 2012

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • inha 09-58

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe